BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23906298)

  • 41. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis.
    Shinozaki M; Hoon DS; Giuliano AE; Hansen NM; Wang HJ; Turner R; Taback B
    Clin Cancer Res; 2005 Mar; 11(6):2156-62. PubMed ID: 15788661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
    Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
    Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DNA methylation in serum of breast cancer patients: an independent prognostic marker.
    Müller HM; Widschwendter A; Fiegl H; Ivarsson L; Goebel G; Perkmann E; Marth C; Widschwendter M
    Cancer Res; 2003 Nov; 63(22):7641-5. PubMed ID: 14633683
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis.
    Faryna M; Konermann C; Aulmann S; Bermejo JL; Brugger M; Diederichs S; Rom J; Weichenhan D; Claus R; Rehli M; Schirmacher P; Sinn HP; Plass C; Gerhauser C
    FASEB J; 2012 Dec; 26(12):4937-50. PubMed ID: 22930747
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Kiss-1/GPR54 protein expression in breast cancer.
    Papaoiconomou E; Lymperi M; Petraki C; Philippou A; Msaouel P; Michalopoulou F; Kafiri G; Vassilakos G; Zografos G; Koutsilieris M
    Anticancer Res; 2014 Mar; 34(3):1401-7. PubMed ID: 24596387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1.
    Zeng H; Irwin ML; Lu L; Risch H; Mayne S; Mu L; Deng Q; Scarampi L; Mitidieri M; Katsaros D; Yu H
    Breast Cancer Res Treat; 2012 May; 133(1):127-35. PubMed ID: 21837478
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
    Naidu R; Wahab NA; Yadav MM; Kutty MK
    Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast.
    Prasad CP; Mirza S; Sharma G; Prashad R; DattaGupta S; Rath G; Ralhan R
    Life Sci; 2008 Aug; 83(9-10):318-25. PubMed ID: 18662704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
    Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
    Fackler MJ; McVeigh M; Evron E; Garrett E; Mehrotra J; Polyak K; Sukumar S; Argani P
    Int J Cancer; 2003 Dec; 107(6):970-5. PubMed ID: 14601057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran.
    Yari K; Payandeh M; Rahimi Z
    Tumour Biol; 2016 Jun; 37(6):8145-52. PubMed ID: 26715274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas.
    Zhou W; Jiang Z; Liu N; Xu F; Wen P; Liu Y; Zhong W; Song X; Chang X; Zhang X; Wei G; Yu J
    J Cancer Res Clin Oncol; 2009 Jan; 135(1):91-102. PubMed ID: 18670789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ras suppressor-1 promotes apoptosis in breast cancer cells by inhibiting PINCH-1 and activating p53-upregulated-modulator of apoptosis (PUMA); verification from metastatic breast cancer human samples.
    Giotopoulou N; Valiakou V; Papanikolaou V; Dubos S; Athanassiou E; Tsezou A; Zacharia LC; Gkretsi V
    Clin Exp Metastasis; 2015 Mar; 32(3):255-65. PubMed ID: 25647720
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma Circulating Cell-free Nuclear and Mitochondrial DNA as Potential Biomarkers in the Peripheral Blood of Breast Cancer Patients.
    Mahmoud EH; Fawzy A; Ahmad OK; Ali AM
    Asian Pac J Cancer Prev; 2015; 16(18):8299-305. PubMed ID: 26745076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression.
    Kechagioglou P; Papi RM; Provatopoulou X; Kalogera E; Papadimitriou E; Grigoropoulos P; Nonni A; Zografos G; Kyriakidis DA; Gounaris A
    Anticancer Res; 2014 Mar; 34(3):1387-400. PubMed ID: 24596386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy.
    Spiliotaki M; Mavroudis D; Kapranou K; Markomanolaki H; Kallergi G; Koinis F; Kalbakis K; Georgoulias V; Agelaki S
    Breast Cancer Res; 2014 Nov; 16(6):485. PubMed ID: 25432416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.
    Li Y; Yang W; Yang Q; Zhou S
    Histol Histopathol; 2012 Apr; 27(4):475-84. PubMed ID: 22374725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer.
    Ramos EA; Camargo AA; Braun K; Slowik R; Cavalli IJ; Ribeiro EM; Pedrosa Fde O; de Souza EM; Costa FF; Klassen G
    BMC Cancer; 2010 Jan; 10():23. PubMed ID: 20109227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.